NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
28/05/2024
Voltar para busca
Dado oficial do USPTO
SYNER-G BIOPHARMA GROUP
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Snapshot rápido
SYNER-G BIOPHARMA GROUP
ST13
US500000097030514Classe
35, 42, 45
Pedido
97030514
Registro
7402524
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
31
Atualização mais recente
28/05/2024
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
35, 42, 45
Data de depósito
16/09/2021
Data de registro
28/05/2024
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
28/05/2024
Última transação
28/05/2024
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Fundamento do pedido
Intent to use
Primeiro uso
20/10/2021
Primeiro uso no comércio
20/10/2021
Código do desenho
4
Tipo de titular
16
Localização do titular
Framingham, MA, US
Examinador
GAYNOR, BARBARA ANNE
Unidade examinadora
M60
Localização atual
PUBLICATION AND ISSUE SECTION
Titulares e representantes
Titulares
SYNER-G BIOPHARMA GROUP LLC
SYNER-G BIOPHARMA GROUP LLC
Syner-G Pharma Consulting, LLC
Representantes
Sara M. Bauer Womble Bond Dickinson (US) LLP
Classificação técnica
Classes Nice
Classe 35Classe 42Classe 45
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 35
Providing business intelligence services in the fields of pharmaceuticalsbiotechnologylife sciences; business consulting services in the fields of pharmaceuticals and biopharmaceuticals and related technologiesspecificallybusiness consulting with respect to clinical developmentformulationevaluationapprovaldeliverycommercializationmarketinglife-cycle management of drugs; business servicesformulation of best practices for drug discoveryformulation developmentclinical suppliespharmacologytoxicologyclinical suppliesclinical development services; regulatory submission managementassisting others in preparing and filing applications for new pharmaceuticals with governmental regulatory bodies
Classe 42
Consulting services in the fields of pharmaceutical research and developmentbiotechnologylife sciences; providing scientific research services in the fields of pharmaceutical design and developmentpharmaceutical chemistrypharmaceutical manufacturing and controls; consulting services regarding research and developmentpharmaceutical drug formulation developmentquality control for others in the fields of pharmaceuticalsbiotechnologylife sciences; technical advisory services in the fields of pharmaceutical research and developmentbiotechnologylife sciences; technical consulting in the fields of pharmaceutical research and developmentbiotechnologylife sciences; technical consulting servicesevaluating the safety of pharmaceutical products in clinical development or in commercial production; consultation services relating to consumer software in the fields of pharmaceuticalsbiotechnologylife sciences; Consulting services for others in the field of designplanningimplementation project management of clinical trial development and clinical trials; Providing technical consulting services in the nature of advising on the testinganalysis and evaluation of the goods of others to determine conformity with certification standards; design and development of computer software for database management in the fields of pharmaceuticalsbiotechnology and life sciences; pharmaceutical drug development services; toxicology services; Scientific research consulting in the field of clinical trial development and clinical trials
Classe 45
Regulatory compliance consulting in the fields of pharmaceuticalsbiotechnologylife sciences
Publicações
Histórico de despachos e eventos da marca no USPTO.
31 publicações encontradas
R.PR
REGISTERED-PRINCIPAL REGISTER
28/05/2024
SUNA
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
24/04/2024
CNPR
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
24/04/2024
SUPC
STATEMENT OF USE PROCESSING COMPLETE
20/04/2024
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
20/04/2024
IUAF
USE AMENDMENT FILED
02/04/2024
EISU
TEAS STATEMENT OF USE RECEIVED
02/04/2024
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
26/10/2023
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
26/10/2023
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
26/10/2023
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
26/10/2023
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
26/10/2023
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
03/10/2023
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
08/08/2023
PUBO
PUBLISHED FOR OPPOSITION
08/08/2023
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
19/07/2023
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
05/07/2023
GNS3
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
03/01/2023
GNSL
LETTER OF SUSPENSION E-MAILED
03/01/2023
CNSL
SUSPENSION LETTER WRITTEN
03/01/2023
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
06/12/2022
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
05/12/2022
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
05/12/2022
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
21/06/2022
GNRT
NON-FINAL ACTION E-MAILED
21/06/2022
CNRT
NON-FINAL ACTION WRITTEN
21/06/2022
DOCK
ASSIGNED TO EXAMINER
21/06/2022
ASGN
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
08/06/2022
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
21/10/2021
NWAP
NEW APPLICATION ENTERED
20/09/2021
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace SYNER-G BIOPHARMA GROUP ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.